CTD Holdings Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,693.30
1,567.40
950.50
1,502.90
1,237.80
1,011.50
Cost of Goods Sold (COGS) incl. D&A
938.30
1,073.60
1,201.20
1,579.80
1,325.60
1,287.10
Gross Income
755.00
493.80
250.70
76.90
87.90
275.60
SG&A Expense
324.90
1,056.10
2,014.70
3,265.30
3,752.80
3,979
EBIT
430.10
562.30
-
3,347.20
3,846.10
4,266.80
Unusual Expense
95.50
-
125.00
810.00
-
-
Non Operating Income/Expense
2.00
-
0.70
48.70
2.80
-
Interest Expense
53.90
33.70
31.30
28.60
-
-
Pretax Income
284.90
592.70
2,431.40
4,223.80
3,833.10
4,255
Income Tax
80.00
-
120.00
-
-
-
Consolidated Net Income
204.90
592.70
2,551.40
4,223.80
3,833.10
4,255
Net Income
204.90
592.70
2,551.40
4,223.80
3,833.10
4,255
Net Income After Extraordinaries
204.90
592.70
2,551.40
4,223.80
3,833.10
4,255
Net Income Available to Common
204.90
592.70
2,551.40
4,223.80
3,833.10
4,255
EPS (Basic)
0.01
0.01
0.05
0.07
0.05
0.05
Basic Shares Outstanding
37,165.80
50,543.10
56,209.40
63,354.50
72,037.20
81,756.80
EPS (Diluted)
0.01
0.01
0.05
0.07
0.05
0.05
Diluted Shares Outstanding
37,165.80
50,543.10
56,209.40
63,354.50
72,037.20
81,756.80
EBITDA
578.10
409.90
2,113.40
3,240.10
3,836.90
4,256.70
Other Operating Expense
-
-
17.00
5.00
5.50
12.20
Non-Operating Interest Income
2.10
3.30
6.70
10.60
10.30
11.80

About CTD Holdings

View Profile
Address
6714 NW 16th Street
Gainesvile Florida 32563
United States
Employees -
Website http://www.ctd-holdings.com
Updated 07/08/2019
CTD Holdings, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The company was founded by C.